BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8703817)

  • 1. Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation.
    Dalley A; Smith JM; Reilly JT; Neil SM
    Br J Haematol; 1996 Jun; 93(4):856-62. PubMed ID: 8703817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis.
    Le Bousse-Kerdilès MC; Martyré MC;
    Pathol Biol (Paris); 2001 Mar; 49(2):153-7. PubMed ID: 11317961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
    Sayinalp N; Cinar H; Uner A; Haznedaroğlu IC; Büyükaşik Y; Göker H; Aksu S; Ozcebe OI; Karakuş S; Kirazli S; Dündar SV
    Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis.
    Le Bousse-Kerdilès MC; Martyré MC
    Ann Hematol; 1999 Oct; 78(10):437-44. PubMed ID: 10550553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow stromal cell distribution of basic fibroblast growth factor in chronic myeloid disorders.
    Yoon SY; Tefferi A; Li CY
    Haematologica; 2001 Jan; 86(1):52-7. PubMed ID: 11146571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marrow fibroblasts from patients with myeloproliferative disorders show increased sensitivity to human serum mitogens.
    Kimura A; Katoh O; Kuramoto A
    Br J Haematol; 1988 Jun; 69(2):153-6. PubMed ID: 3390390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raised urinary calmodulin levels in idiopathic myelofibrosis: possible implications for the aetiology of fibrosis.
    Eastham JM; Reilly JT; Mac Neil S
    Br J Haematol; 1994 Mar; 86(3):668-70. PubMed ID: 8043453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinico-Pathological Profile And Outcomes Of Patients With Polycythaemia Vera, Essential Thrombocythaemia And Idiopathic Myelofibrosis: A Tertiary Care Center Experience From Southern Pakistan.
    Shaikh MS; Shaikh MU; Adil SN; Khurshid M; Ahmed ZA
    J Ayub Med Coll Abbottabad; 2016; 28(2):293-297. PubMed ID: 28718562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis.
    Burstein SA; Malpass TW; Yee E; Kadin M; Brigden M; Adamson JW; Harker LA
    Br J Haematol; 1984 Jul; 57(3):383-92. PubMed ID: 6743563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders.
    Martyré MC
    Leuk Lymphoma; 1995 Dec; 20(1-2):39-44. PubMed ID: 8750621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of interferon-alpha in the treatment of idiopathic myelofibrosis.
    Bachleitner-Hofmann T; Gisslinger H
    Ann Hematol; 1999 Dec; 78(12):533-8. PubMed ID: 10647876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant expression of insulin-like growth factor-2 (IGF-2) in Philadelphia chromosome negative chronic myeloproliferative disorders.
    Bock O; Tessema M; Serinsöz E; von Wasielewski R; Büsche G; Kreipe H
    Leuk Res; 2004 Nov; 28(11):1145-51. PubMed ID: 15380337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet-derived mitogenic activity and bone marrow fibrosis in myeloproliferative disorders.
    Romano M; Viero P; Cortellazzo S; Barbui T; Donati MB; Poggi A
    Haemostasis; 1990; 20(3):162-8. PubMed ID: 2143744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral T-cell lymphoma presenting as myelofibrosis with the expression of basic fibroblast growth factor.
    Kikukawa M; Umahara T; Kikawada M; Kanaya K; Sakurai H; Shin K; Mori M; Iwamoto T
    Geriatr Gerontol Int; 2009 Dec; 9(4):395-8. PubMed ID: 20002760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Occurrence of myelofibrosis in individual types of chronic myeloproliferative diseases].
    Adamkov M; Plank L; Szépe P
    Bratisl Lek Listy; 1998 May; 99(5):240-4. PubMed ID: 9673037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Properties of myelofibrosis-derived fibroblasts.
    Castro-Malaspina H; Jhanwar SC
    Prog Clin Biol Res; 1984; 154():307-22. PubMed ID: 6382300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.
    Kreft A; Büche G; Ghalibafian M; Buhr T; Fischer T; Kirkpatrick CJ
    Acta Haematol; 2005; 113(2):137-43. PubMed ID: 15802893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of PDGF on myeloproliferative disorders].
    Kimura A; Katoh O; Kuramoto A
    Rinsho Ketsueki; 1988 Jul; 29(7):989-93. PubMed ID: 3184485
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.